Methylprednisolone Pulses Plus Tacrolimus in Addition to Standard of Care vs. Standard of Care Alone in Patients With Severe COVID-19. A Randomized Controlled TrialMedicine Published on 2021-06-142022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] 95% CI addition Administered adverse event all-cause mortality assigned clinical combined use conducted control group Controlled COVID-19 COVID-19 patients cumulative dose Efficacy and safety evaluate event experimental group hazard ratio hospitalized patient Identifier IMPROVE Infection Inflammation Inflammatory inhibitors limitations limited sample size Lung injury median Methylprednisolone non-randomized study non-serious adverse Open-label Patient Primary outcome pulse randomization Randomized RCT receiving SARS-CoV-2 secondary outcome Secondary outcomes severe COVID-19 significantly significantly lower single-center SOC stability Stage Standard Standard of care statistically significant subsequent tacrolimus the SARS-CoV-2 therapy Treatment Trial triggered two groups [DOI] 10.3389/fmed.2021.691712 PMC 바로가기 [Article Type] Medicine
Impact of Prophylactic Hydroxychloroquine on People at High Risk of COVID-19: A Systematic Review and Meta-AnalysisReview Published on 2021-06-132022-10-30 Journal: Journal of Clinical Medicine [Category] COVID-19, [키워드] 95% CI abdominal pain adverse events all-cause mortality Cohort compatible symptoms controls COVID-19 COVID-19 infection COVID-19 infections COVID-19 symptoms defined diarrhea did not reduce Effect Efficacy Evidence FIVE Hydroxychloroquine Impact increased the risk Intervention Meta-analysis no difference no effect outcome outcomes performed positive RT-PCR Prophylactic Prophylaxis Quality Randomized controlled trial RCT RCTs review RT-PCR Safety searched Secondary outcomes usual care vomiting worsening [DOI] 10.3390/jcm10122609 PMC 바로가기 [Article Type] Review
Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide EvidenceMedicine Published on 2021-06-072022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] aggregate approach arising benefit contribute convalescent plasma Convalescent plasma therapy coronavirus disease Course COVID-19 COVID-19 patient demonstrated Efficacy Evidence greater health emergency healthcare IMPROVE Infectious disease Kaplan–Meier Kaplan–Meier survival plot Kaplan–Meier survival plots Kaplan–Meier analysis meta-analytical mosaic Outbreaks passive antibody transfer Patient patient mortality patient survival patients hospitalized performed plasma prevent disease progression provided Qualitative Randomized controlled trial RCT RCTs reported required safety profile SARS-CoV-2 supportive therapies survival the disease transfused treat viral clearance [DOI] 10.3389/fmed.2021.684151 PMC 바로가기 [Article Type] Medicine
Efficacy and Safety of Hydroxychloroquine for Hospitalized COVID-19 Patients: A Systematic Review and Meta-AnalysisReview Published on 2021-06-052022-10-30 Journal: Journal of Clinical Medicine [Category] COVID-19, [키워드] 95%CI adverse events all-cause mortality analyses caused clearance clinical recovery Controlled trial controls COVID-19 discharge dose Efficacy and safety Hospitalization hospitalized COVID-19 hospitalized COVID-19 patient hospitalized COVID-19 patients Hydroxychloroquine ICU admission increased mortality inverse mechanical ventilation Meta-analysis Mortality non-invasive ventilation not affect outcome oxygen support performed Pneumonia radiological progression random effect ranged RCT RCTs review SAE Safety searched secondary Secondary outcomes Serious Adverse Event severe adverse events significantly higher subgroup analysis Treatment worsening [DOI] 10.3390/jcm10112503 PMC 바로가기 [Article Type] Review
Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysisResearch Article Published on 2021-06-022022-10-31 Journal: F1000Research [Category] COVID-19, MERS, [키워드] Analysis articles CCP convalescent plasma coronavirus disease COVID-19 COVID-19 patients Cross-sectional studies Efficacy Egger test FIVE heterogeneity higher risk Jadad scale Meta-analysis Mortality mortality rate outcomes passive immunization Patient patients treated plasma Prospective Study Randomized controlled trial RCT reduce Research retrospective risk searched severe COVID-19 standard treatment therapy treated Treatment Web of Science were assessed [DOI] 10.12688/f1000research.36396.3 PMC 바로가기 [Article Type] Research Article
Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysisSARS-CoV-2 감염에 대한 하이드록시클로로퀸/클로로퀸의 효능 및 안전성: 체계적 고찰 및 메타분석Meta-Analysis Published on 2021-06-012022-09-11 Journal: Journal of infection and chemotherapy : official j [Category] 치료제, [키워드] 95% CI adverse event adverse events Azithromycin Care Chloroquine control group coronavirus Corticosteroids COVID-19 did not reduce drug Effect Efficacy Efficacy and safety evaluated Evidence excluded HCQ HCQ therapy Hospitalization hospitalized patients Hydroxychloroquine hydroxychloroquine/chloroquine immunomodulators increase in Intervention Meta-analysis Mortality Participants patients with COVID-19 performed Prophylaxis prospective cohort study Randomized controlled trial Randomized controlled trials RCT RCTs risk SARS-CoV-2 SARS-COV-2 infection searched significantly higher systematic review therapy Treatment Web of Science [DOI] 10.1016/j.jiac.2021.02.021 PMC 바로가기 [Article Type] Meta-Analysis
Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials코로나19에서의 토실리주맙: 무작위 대조 시험의 메타 분석, 시험 순차 분석 및 메타 회귀Meta-Analysis Published on 2021-06-012022-09-11 Journal: Intensive care medicine [Category] Fulltext, SARS, 임상, 진단, [키워드] adjusted Admission benefit Beta Composite conducted control group COVID-19 defined did not reduce disease Evidence excluded hospitalized COVID-19 patients ICU ICU admission IL-6 IL-6 blockade IL-6 inhibition Immunologic Immunologic factors interleukin interleukin-6 mechanical ventilation Meta-analysis meta-regression Mild Mortality mortality risk outcome Patient patients with COVID-19 pharmacological intervention pharmacological interventions Placebo Primary outcome randomized-controlled RCT RCTs reduce reducing Regression reported required risk secondary secondary outcome Secondary outcomes sequential analysis severe COVID-19 severe disease standard care suggested systematic review therapeutic strategy Tocilizumab Treatment Trial trial sequential analysis TSA [DOI] 10.1007/s00134-021-06416-z PMC 바로가기 [Article Type] Meta-Analysis
The COVID-19 pandemic: An opportunity to rethink and harmonise the frequency of follow-up visits for patients with early stage breast cancerCOVID-19 범유행: 초기 유방암 환자의 후속 방문 빈도를 재고하고 조화시킬 수 있는 기회Article Published on 2021-06-012022-09-11 Journal: Cancer treatment reviews [Category] SARS, 임상, [키워드] adverse effect adverse effects assessment Bia Breast Breast cancer breast cancer patient changes in citation Clinical practice Cohort studies collaboration completion COVID-19 COVID-19 pandemic database disease disease free survival early stage eligible Endpoint evaluate Evidence examined finding Follow-up Follow-up interval. Follow-up visit Frequency had no IMPROVE independent initial initial treatment library life Patient prospective cohort study Quality Quality of life Randomized controlled trial Randomized controlled trials RCT RCTs reduced reduction in RoB scale searched statistically significant difference survival systematic review Treatment Trial was performed were assessed while [DOI] 10.1016/j.ctrv.2021.102188 PMC 바로가기 [Article Type] Article
Protecting older patients with cardiovascular diseases from COVID-19 complications using current medicationsSpecial Article Published on 2021-05-252022-10-31 Journal: European Geriatric Medicine [Category] COVID-19, MERS, SARS, [키워드] ACE acute phase Analysis Angiotensin receptor blockers Antiarrhytmic Anticoaculant Anticoagulants arrhythmia Aspirin authors benefit cardiovascular disease cardiovascular diseases Coagulopathy Colchicine Comorbidities complications condition Consensus COVID-19 COVID-19 complication COVID-19 patient database diabetes drug drugs Endothelial dysfunction enzyme Evidence finding frailty general condition include Inflammation inhibitors medication message MOST NSAID NSAIDS observational studies observational study older patient Pathogenesis patients with COVID-19 PROTECT Protecting Protective RAAS randomised controlled trial RCT RCTs recommendation Result retrospective severe COVID-19 statin supplementary material Therapies Treatment Vascular Vitamin D [DOI] 10.1007/s41999-021-00504-5 PMC 바로가기 [Article Type] Special Article
Vitamin D supplementation for the treatment of COVID-19: a living systematic reviewCOVID-19 치료를 위한 비타민 D 보충: 살아있는 체계적인 검토Article Published on 2021-05-242022-09-11 Journal: The Cochrane database of systematic reviews [Category] 임상, [키워드] 95% CI 95% confidence interval acute respiratory syndrome addressed Administered adverse event adverse events age all-cause mortality approach Arm Asymptomatic Asymptomatic disease baseline benefit Blood level blood levels calcifediol certainty certainty of evidence cholecalciferol clinical clinical status Cochrane COVID-19 Study Register comparability Consistency control group control groups coronavirus disease coronavirus diseases COVID-19 COVID-19 symptoms daily dose Data collection death decrease described determine died disease disease severity dose effective Effectiveness Effects Ethnicity event Evidence excluded Gender Health Organization heterogeneity High dose higher risk hospital discharge hypercalcaemia identify include indicate individual individuals inflammatory markers information Invasive mechanical ventilation investigated life maintain MERS methodological methodology Middle East Middle East respiratory syndrome Mild Mild disease moderate moderate or severe disease moderate to severe Mortality multiple dose multiple doses nine oral calcifediol oral cholecalciferol outcome outcomes participant Participants people with COVID-19 Placebo placebo group placebo treatment Population progression Quality Quality of life randomisation randomised controlled trial Randomised controlled trials RCT RCTs recording reported required risk of bia risk ratio Safe Safety searched Selection selective Serious Adverse Event Serious Adverse Events Severe acute respiratory syndrome severe disease Standard of care subject syndrome systematic review the placebo group the WHO treated Treatment treatment for COVID-19 treatment of COVID-19 viral clearance Vitamin D vitamin D serum Vitamin D status Vitamin D supplementation vomiting Web of Science WHO World Health Organization [DOI] 10.1002/14651858.CD015043 PMC 바로가기 [Article Type] Article